The performance of the three putative GBM recurrence biomarkers (GGH, GRN and ITM2B; Fig. 4b, c-1) were assessed by ROC analyses, each revealing excellent sensitivity and specificity in distinguishing Post-OP from REC specimens with AUC > 0.92 (Fig. 4c-2). This evidence concerns the gene GGH and glioblastoma.